Skip to content
Home/ Molecular Characterization of Prolactin in Ovarian Tumors by Radiobinding Assay: Prolactin in Ovaria
Molecular Characterization of Prolactin in Ovarian Tumors by Radiobinding Assay: Prolactin in Ovaria

Molecular Characterization of Prolactin in Ovarian Tumors by Radiobinding Assay: Prolactin in Ovaria

by Yousif, Hiba Itemad
No customer reviews yet ISBN 9781511959285 CreateSpace Independent Publishing Platform

The developed protocol for the assay of hPRL is suitable for the assessment of PRL in tissues of patients with benign and malignant serous ovarian tumors.A higher incidence of prolactin was obtained in malignant than in benign serous ovarian tumors in tissues and sera.The kinetic studies of 125I-anti hPRL antibody with hPRL in premenopausal and postmenopausal patients with benign and malignant serous ovarian tumors showed that the binding reaction is a temperature and time dependent process. The results indicate that the reaction fits pseude-first order kinetic.The results obtained from the thermodynamics studies on the association of 125I-anti hPRL antibody with hPRL in benign and malignant serous ovarian tumors were spontaneously occurred and the binding reactions were entropically driven.The spectroscopic studies revealed that each of (125I-anti hPRL antibody/PRL) complex and 125I-anti hPRL antibody has a characteristic spectrum.

About the author

Product details

BrandCreateSpace Independent Publishing Platform
Pub dateMay 11, 2015
ISBN-101511959282
ISBN-139781511959285
LanguageEnglish
Dimensions9.61 × 0.57 × 6.69 in
Weight1 lb
Last updated 2026-03-11 03:29
$34.95 $40.00 12% off
You save $5.05 · list price $40.00
In stock — ships in 24 hours with free tracking
Delivery by Monday, September 14, 2026
Qty
Sign in to Add to Saved list
Free delivery on orders over $35.
15-day returns. Any reason.
Secure checkout. We never store card details.

Readers who bought this also bought

More from Chemistry - Clinical
See all
Advances in Synthetic Organic Chemistry and Methods Reported in Us Patents
Thomas F DeRosa
$270.00
Advances in Clinical Chemistry: Volume 43
Volume 43 of the <b>Advances in Clinical Chemistry</b> series contains review articles of wide interest to clinical laboratory scientists and diagnostic adventurers. In this volume, the biochemistry of bilirubin, the end-product of heme metabolism, is explored with respect to its potential beneficial role in preventing oxidative changes associated with a variety of pathological conditions, including atherosclerosis, cancer, and inflammatory, autoimmune and other degenerative diseases.
$271.73
Advances in Clinical Chemistry: Volume 49
Volume 49 in the internationally acclaimed <i>Advances in Clinical Chemistry</i> contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics ranging from basic biochemical exploration to cutting-edge microarray technology.
$254.40
Annual Reports in Medicinal Chemistry: Volume 46
<i>Annual Reports in Medicinal Chemistry </i>provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
$208.20
Annual Reports in Medicinal Chemistry: Volume 47
<i>Annual Reports in Medicinal Chemistry </i>provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
$197.81
Advances in Clinical Chemistry: Volume 66
<p>Volume 66 in the internationally acclaimed <i>Advances in Clinical Chemistry</i> contains chapters authored by world renowned clinical laboratory scientists, physicians and research scientists. The serial provides the latest and most up-to-date technologies related to the field of Clinical Chemistry and is the benchmark for novel analytical approaches in the clinical laboratory.</p>
$237.08